Hims & Hers Health Inc

Hims & Hers Health, Inc. (NYSE: HIMS) provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss.

Key Business and Financial Updates:

• Strong Revenue Growth and Expanding Subscriber Base: Hims & Hers Health, Inc. reported robust financial performance for FY2025, with total revenue increasing 59% year-over-year to approximately USD 2.35 billion, driven by continued subscriber growth, deeper customer engagement, and expansion across healthcare specialties. The company’s subscriber base surpassed 2.5 million users, reflecting 13% annual growth, while monthly revenue per average subscriber increased to USD 83, demonstrating improved monetization and cross-specialty adoption. Management highlighted that the platform’s increasing scale and personalized healthcare approach continue to support long-term consumer adoption and retention.
• Platform Diversification and International Expansion Initiatives: During 2025, the company continued expanding its healthcare ecosystem through the introduction of hormone therapies, diagnostics capabilities, and its Labs platform aimed at enhancing personalized health insights. The business also accelerated international expansion initiatives, contributing to significant growth in rest-of-world revenue. International revenue increased substantially during the year, reflecting the company’s strategic focus on extending its consumer health platform beyond the United States. Management indicated that ongoing investments in technology, infrastructure, and global market expansion are intended to position the company as a leading consumer-centric healthcare platform over the long term.
• Profitability Trends and Margin Performance: For FY2025, net income totaled approximately USD 128 million, while Adjusted EBITDA increased significantly to USD 318 million from USD 176.9 million in the prior year, reflecting improved operational leverage and revenue scale. Gross margin for the year stood at 74%, compared to 79% in FY2024, primarily reflecting evolving product mix and continued investments in platform expansion. In the fourth quarter of 2025, revenue increased 28% year-over-year to USD 617.8 million, while quarterly Adjusted EBITDA reached USD 66.3 million. Despite margin moderation and lower free cash flow generation during the quarter, the company maintained positive profitability supported by continued operating scale and customer growth.
• Cash Flow Generation and Financial Position: The company generated approximately USD 300 million in operating cash flow during FY2025, compared to USD 251.1 million in the prior year, reflecting strong underlying operating performance and cash generation capabilities. Although free cash flow declined to USD 57.4 million from USD 198.3 million in FY2024, management noted that the company continues to maintain a strong balance sheet and sufficient financial flexibility to support investments in new specialties, infrastructure development, technological capabilities, and international growth initiatives. The company emphasized that mature domestic specialties continue to provide meaningful operating cash flow support for future expansion activities.
• FY2026 Outlook and Long-Term Strategic Targets: Looking ahead, Hims & Hers Health, Inc. provided FY2026 guidance projecting revenue in the range of USD 2.7 billion to USD 2.9 billion and Adjusted EBITDA between USD 300 million and USD 375 million. The outlook assumes continued availability of compounded semaglutide offerings and excludes potential contributions from the proposed acquisition of Eucalyptus, which is expected to close during mid-2026 subject to regulatory approvals. Management reiterated its long-term strategic objectives targeting at least USD 6.5 billion in revenue and USD 1.3 billion in Adjusted EBITDA by 2030, supported by continued platform diversification, international expansion, and personalized healthcare adoption trends.

Key Risks for HIMS:

• Dependence on GLP-1 and Compounded Semaglutide Availability: A significant near-term risk for Hims & Hers Health, Inc. relates to its continued ability to offer compounded semaglutide products through its platform. The company’s FY2026 outlook explicitly assumes the ongoing availability of compounded semaglutide and no adverse changes in current business relationships. Any tightening of regulatory oversight by the U.S. Food and Drug Administration, changes in compounding regulations, or reduced access to GLP-1 supply could negatively impact customer growth, revenue momentum, and profitability within its weight-management segment.
• Margin Pressure from Expansion and Product Mix Shift: Although revenue growth remains strong, the company experienced gross margin compression during FY2025, with gross margin declining from 79% in FY2024 to 74% in FY2025. Continued investments in international expansion, diagnostics, infrastructure, technology, and newer healthcare specialties may further pressure profitability in the near-to-medium term. In addition, expansion into lower-margin categories and rising customer acquisition costs could limit operating leverage if revenue growth moderates over time.
• Regulatory, Competitive, and Execution Risks in Digital Healthcare: The digital healthcare industry remains highly competitive and heavily regulated, exposing Hims & Hers Health, Inc. to evolving compliance, licensing, telehealth, and data privacy requirements across multiple jurisdictions. The company’s aggressive international expansion strategy and broader healthcare diversification also introduce execution risks related to operational scalability, physician network management, customer retention, and integration of new services or acquisitions such as Eucalyptus. Increasing competition from telehealth providers, pharmacies, insurers, and large healthcare platforms could also affect pricing power and long-term market share expansion.

Technical Observation (on the daily chart):

• Trend Reversal Structure and Moving Average Alignment: Hims & Hers Health, Inc. continues to exhibit improving medium-term technical momentum following a prolonged corrective decline from the USD 70 region toward the USD 14 support zone earlier in the year. The stock has now established a constructive recovery structure, supported by sustained price action above both the 21-day and 50-day moving averages. Importantly, the shorter-duration moving average has continued trending upward while maintaining a positive spread versus the longer-duration trend indicator, reflecting strengthening directional momentum and improving market sentiment. The recent consolidation above the USD 27–29 range also suggests a transition from stabilization toward a potential continuation phase, while the stock’s ability to sustain higher lows indicates improving accumulation behavior from market participants.
• Momentum Indicators and Volume Confirmation: The Relative Strength Index (RSI-14) is currently positioned near the 60 level, reflecting constructive bullish momentum without entering materially overbought territory. The RSI structure has remained consistently above the neutral 50 threshold during recent trading activity, suggesting strengthening demand conditions and improving trend persistence. Additionally, momentum recovery has been accompanied by intermittent increases in trading volume during upward price moves, indicating improving institutional participation and healthier buying interest. The current momentum profile suggests that bullish sentiment remains intact, although a sustained move above the RSI 65–70 zone would likely be required to confirm a stronger acceleration phase. Continued stability in volume participation alongside supportive momentum conditions may enhance the probability of additional upside continuation toward higher resistance bands.
• Key Support, Resistance, and Forward Technical Outlook: From a broader technical perspective, the USD 26–27 range now represents a key medium-term support region supported by both moving average convergence and prior consolidation activity. A sustained hold above this zone would preserve the stock’s improving technical structure and support the possibility of continued recovery momentum. On the upside, immediate resistance is visible near the USD 30–32 region, followed by a more substantial resistance zone around USD 38–40 where prior supply pressure and breakdown activity previously emerged. A decisive breakout above these levels accompanied by stronger volume expansion could potentially trigger accelerated momentum buying and broader trend-following participation. Conversely, failure to maintain support above the moving averages may result in renewed consolidation or a retest of lower support levels. Overall, the current technical configuration reflects improving medium-term sentiment and strengthening trend stabilization, although confirmation of a durable long-term bullish reversal would still require sustained breakout validation and continued institutional accumulation.

Hims & Hers Health, Inc. continues to strengthen its position within the digital healthcare and wellness industry through expanding subscriber scale, platform diversification, and growing international presence. The company delivered strong FY2025 revenue growth supported by increased engagement across healthcare specialties, improving monetization trends, and broader adoption of its personalized healthcare offerings. At the same time, the business continues investing in diagnostics, infrastructure, technology capabilities, and global expansion initiatives to support long-term growth objectives. While profitability and operating cash flow generation remained positive, margin moderation, regulatory dependence surrounding compounded GLP-1 offerings, and execution risks associated with rapid expansion remain key areas to monitor. From a technical perspective, the stock has shown signs of medium-term stabilization and improving momentum following a prolonged correction, although sustained breakout confirmation and stronger volume participation may be required to validate a broader long-term uptrend.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been Hims & Hers Health, Inc. (NYSE: HIMS) at the closing market price of USD 29.14, as of May 11, 2026. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective, and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 11, 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.